Neurexis Therapeutics on Muck Rack

Neurexis Therapeutics

As seen in: PRWeb
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Neurexis

Contact Neurexis, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Oxygen/glucose-deprivation causes long-term impairment of synaptic CaMKII movement

|
By Olivia R. Buonarati, Nidia Quillinan, K. Ulrich Bayer, Neurexis Therapeutics
| biorxiv.org
Abstract Learning and memory are thought to require hippocampal long-term potentiation (LTP), a form of synaptic plasticity that is persistently impaired after cerebral ischemia and that requires movement of the Ca2+/calmodulin-dependent protein kinase II (CaMKII) to excitatory synapses. We show here that oxygen/glucose-deprivation (OGD) in cultures hippocampal neurons causes a long-lasting impairment of CaMKII movement.
Open in Who Shared Issue with article?

Neurexis Therapeutics Secures $3 Million NIH Grant to Advance Neuroprotective Treatment for Global Cerebral Ischemia Original

|
By Neurexis Therapeutics
| PRWeb
A promising approach for preventing cognitive and behavioral impairment following ischemia , /PRNewswire-PRWeb/ -- Neurexis Therapeutics, a leading biopharmaceutical company focused on developing neuroprotective interventions, has been awarded a prestigious $3 million Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH).
Open in Who Shared View Duplicates (13) Issue with article?

Neurexis Therapeutics: New Discoveries Could Revolutionize Treatment of Alzheimer's and Other Neurological Conditions Original

|
By Neurexis Therapeutics
| PRWeb
Results published in the journal Nature confirm critical role of Calcium Calmodulin Kinase II (CaMKII) enzyme , /PRNewswire-PRWeb/ -- Neurexis Therapeutics, a biotechnology company committed to reshaping the landscape of neuroprotection, is excited to highlight recent groundbreaking research that could unlock new avenues for Alzheimer's disease and other brain disease therapies.
Open in Who Shared View Duplicates (4) Issue with article?
See all 3 articles

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Neurexis

Contact Neurexis, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified